Comparative Pharmacology
Head-to-head clinical analysis: DEXACEN 4 versus METHYLPREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACEN 4 versus METHYLPREDNISOLONE ACETATE.
DEXACEN-4 vs METHYLPREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
None Documented
None Documented
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Category C
Category D/X
Corticosteroid
Corticosteroid